Abstract:Macroautophagy/autophagy is an evolutionarily conserved pathway responsible for clearing cytosolic aggregated proteins, damaged organelles or invading microorganisms. Dysfunctional autophagy leads to pathological accumulation of the cargo, which has been linked to a range of human diseases, including neurodegenerative diseases, infectious and autoimmune diseases and various forms of cancer. Cumulative work in animal models, application of genetic tools and pharmacologically active compounds, has suggested the potential therapeutic value of autophagy modulation in disease, as diverse as Huntington, Salmonella infection, or pancreatic cancer. Autophagy activation versus inhibition strategies are being explored, while the role of autophagy in pathophysiology is being studied in parallel. However, the progress of preclinical and clinical development of autophagy modulators has been greatly hampered by the paucity of selective pharmacological agents and biomarkers to dissect their precise impact on various forms of autophagy and cellular responses. Here, we summarize established and new strategies in autophagy-related drug discovery and indicate a path toward establishing a more efficient discovery of autophagy-selective pharmacological agents. With this knowledge at hand, modern concepts for therapeutic exploitation of autophagy might become more plausible.Abbreviations: ALS: amyotrophic lateral sclerosis; AMPK: AMP-activated protein kinase; ATG: autophagy-related gene; AUTAC: autophagy-targeting chimera; CNS: central nervous system; CQ: chloroquine; GABARAP: gamma-aminobutyric acid type A receptor-associated protein; HCQ: hydroxychloroquine; LYTAC: lysosome targeting chimera; MAP1LC3/LC3: microtubule associated protein 1 light chain 3; MTOR: mechanistic target of rapamycin kinase; NDD: neurodegenerative disease; PDAC: pancreatic ductal adenocarcinoma; PE: phosphatidylethanolamine; PIK3C3/VPS34: phosphatidylinositol 3-kinase catalytic subunit type 3; PtdIns3K: class III phosphatidylinositol 3-kinase; PtdIns3P: phosphatidylinositol 3-phosphate; PROTAC: proteolysis-targeting chimera; SARS-CoV-2: severe acute respiratory syndrome coronavirus 2; SQSTM1/p62: sequestosome 1; ULK1: unc-51 like autophagy activating kinase 1.

Deubiquitinating Enzymes Related to Autophagy: New Therapeutic Opportunities?

Deubiquitinating enzymes (DUBs): decipher underlying basis of neurodegenerative diseases

Deubiquitylating enzymes in neuronal health and disease

Mechanisms of regulation and diversification of deubiquitylating enzyme function

Regulation of Deubiquitinating Enzymes by Post-Translational Modifications

Regulation of Autophagy in Neurodegenerative Diseases: A Brief Review on Autophagy Therapy for Neurodegenerative Diseases

High-throughput screening of functional deubiquitinating enzymes in autophagy

Targeting autophagy in disease: established and new strategies

A review of deubiquitinases and thier roles in tumorigenesis and development

Neuronal Autophagy: Regulations and Implications in Health and Disease

Deubiquitinases in cancer

Post-Translational Modifications of Deubiquitinating Enzymes: Expanding the Ubiquitin Code

The emerging role and therapeutic implications of bacterial and parasitic deubiquitinating enzymes

Autophagy Intertwines with Different Diseases—Recent Strategies for Therapeutic Approaches

Deubiquitylation of deubiquitylases

On the Study of Deubiquitinases: Using the Right Tools for the Job

Deubiquitylating Enzymes in Cancer and Immunity

Functional analysis of deubiquitylating enzymes in tumorigenesis and development

Autophagy: cellular and molecular mechanisms

Compromised autophagy and neurodegenerative diseases

Ubiquitination and deubiquitination in cancer: from mechanisms to novel therapeutic approaches